Olmesartanmedoxomil/Amlodipine Accord (Olmesartan Medoxomil, Amlodipine)

Olmesartan/Amlodipine Accord is a fixed‑dose combination that targets the renin‑angiotensin system and vascular smooth‑muscle calcium channels to control high blood pressure.

• Hypertension: provides additive blood‑pressure reduction for patients not adequately controlled on a single agent.
• Essential hypertension: achieves target systolic and diastolic pressures with once‑daily dosing.
• Resistant hypertension (as adjunct): offers an alternative pathway when additional agents are needed.

• Olmesartan medoxil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Amlodipine inhibits L‑type calcium channels in vascular smooth muscle, causing arterial dilation. The combined blockade reduces peripheral vascular resistance and lowers both systolic and diastolic blood pressure more effectively than either component alone.

Adverse reactions may occur with any antihypertensive therapy.

Common Side Effects

• Dizziness: transient light‑headedness, especially after the first dose.
• Headache: mild to moderate intensity, often resolves with continued use.
• Peripheral edema: swelling of ankles or feet due to vasodilation.
• Flushing: temporary warmth and reddening of the skin.
• Fatigue: general tiredness without exertion.
• Palpitations: awareness of heartbeat, usually benign.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue, or airway requiring emergency care.
• Severe hypotension: marked drop in blood pressure leading to fainting or shock.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Myocardial infarction: rare occurrence of heart attack, especially in patients with existing coronary disease.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.

• Renal impairment: assess kidney function and adjust dose if necessary.
• Hepatic impairment: use with caution; monitor liver enzymes.
• Pregnancy: contraindicated due to risk of fetal toxicity; avoid in women of child‑bearing potential.
• Elderly: start at the lowest dose and titrate slowly.
• Electrolyte imbalance: monitor serum potassium, especially when combined with diuretics.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Olmesartan/Amlodipine may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• ACE inhibitors: combined use can increase risk of hyperkalemia and renal dysfunction.
• Potassium‑sparing diuretics: may precipitate dangerous hyperkalemia.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise amlodipine plasma levels, increasing hypotension risk.
• NSAIDs: can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Thiazide or loop diuretics: additive blood‑pressure lowering; monitor for volume depletion.
• Other antihypertensives: may enhance hypotensive effect; adjust dose as needed.
• Rifampin: induces CYP3A4, reducing amlodipine concentrations.
• Grapefruit juice: can increase amlodipine exposure; advise limited consumption.